STAT Plus: Four big questions ahead of Moderna’s public debut — biotech’s biggest ever
RUBY WALLAU FOR STAT
Before Moderna Therapeutics tests investors' appetite, here’s a guide to the outstanding questions pegged to biotech’s most scrutinized unicorn.
.png)
No hay comentarios:
Publicar un comentario